MikeTrendsTrends right now
AI: reposAPI

search

Anktiva

Trends

  1. 1
    ImmunityBio's Anktiva wins US label expansion for bladder cancer●ImmunityBio’s bladder cancer drug, Anktiva lands US label expansion✉newsTechnology3 d ago

    ImmunityBio's bladder cancer drug Anktiva has received a label expansion in the United States, widening the approved uses of the therapy. The approval allows the immunotherapy to be used in more patients with the disease, strengthening ImmunityBio's position in the bladder cancer treatment market and giving clinicians an additional option for care.

  2. 2
    ImmunityBio slides despite Anktiva FDA win as investors wait▼IBRX Stock Eyes Weekly Slump Despite Anktiva FDA Win — Retail Stays Cautious Ahead Of Founder’s Trial Talk✉newsBusinessRetail3 d ago

    ImmunityBio (IBRX) shares are heading for a weekly decline even after a positive FDA development for Anktiva, the company's cancer immunotherapy. Retail investors remain cautious, with attention focused on remarks expected from founder Patrick Soon-Shiong regarding a trial. Investors appear unconvinced the regulatory win is enough to offset concerns about the company's clinical pipeline and spending.